Last updated on December 2019

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors


Brief description of study

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.

Detailed Study Description

The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in children and adults.

Secondary objectives comprise the efficacy and safety of larotrectinib in different NTRK-tumor types.

Clinical Study Identifier: NCT02576431

Find a site near you

Start Over

Stanford Cancer Center

Palo Alto, CA United States
  Connect »

UCLA-Santa Monica Medical Center

Santa Monica, CA United States
  Connect »

Memorial Hospital West

Pembroke, FL United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Wake Forest Baptist Health

Winston-Salem, NC United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

Avera Cancer Institute

Sioux Falls, SD United States
  Connect »

Inova Health Care Services

Falls Church, VA United States
  Connect »

University of Washington

Seattle, WA United States
  Connect »

West Virginia University

Morgantown, WV United States
  Connect »

Finsen Centre

Copenhagen, Denmark
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

IPO Porto

Porto, Portugal
  Connect »